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Abstract  
Background: Currently, no consensus exists on a model describing endogenous glucose 
production (EGP) as a function of glucagon concentrations. Reliable simulations to 
determine the glucagon dose preventing or treating hypoglycemia or to tune a dual-
hormone artificial pancreas control algorithm need a validated glucoregulatory model 
including the effect of glucagon.  
Methods: Eight type 1 diabetes (T1D) patients each received a subcutaneous (SC) bolus 
of insulin on four study days to induce mild hypoglycemia followed by a SC bolus of 
saline or 100, 200 or 300 µg of glucagon.  Blood samples were analyzed for 
concentrations of glucagon, insulin and glucose. We fitted pharmacokinetic (PK) models 
to insulin and glucagon data using maximum likelihood and maximum a posteriori 
estimation methods. Similarly, we fitted a pharmacodynamic (PD) model to glucose data. 
The PD model included multiplicative effects of insulin and glucagon on EGP. Bias and 
precision of PD model test-fits were assessed by mean predictive error (MPE) and mean 
absolute predictive error (MAPE). 
Results: Assuming constant variables in a subject across non-outlier visits and using 
thresholds of ±15% MPE and 20% MAPE, we accepted at least one and at most three PD 
model test-fits in each of the seven subjects. Thus, we successfully validated the PD 
model by leave-one-out cross-validation in seven out of eight T1D patients.  
Conclusions: The PD model accurately simulates glucose excursions based on plasma 
insulin and glucagon concentrations. The reported PK/PD model including equations and 
fitted parameters allows for in silico experiments that may help improve diabetes 
treatment involving glucagon for prevention of hypoglycemia.   
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Introduction 
The treatment goal for patients with type 1 diabetes is near-normalization of plasma 
glucose levels. Few patients achieve this even with intensive insulin treatment [1]. New 
approaches with automatic glucose controlled insulin and glucagon delivery, known as a 
dual-hormone artificial pancreas (AP), may offer a solution to improve glycemic control 
[2-6]. To design and tune control algorithms for AP devices prior to in vivo tests, a 
validated simulation model capturing the dynamics between glucose, insulin and 
glucagon is needed to perform helpful in silico experiments [7-9].  
Glucagon primarily affects hepatic glucose production by increasing glycogenolysis, 
while the rate of gluconeogenesis seems less affected by changes in both insulin and 
glucagon concentrations [10]. Currently marketed glucagon is approved as a 1 mg rescue-
treatment for severe hypoglycemia, although the interest in mini-dose glucagon is 
increasing [11, 12]. Recent studies proved that the glycemic response to low-dose 
glucagon is dependent on ambient insulin levels [13], but neither on plasma glucose level 
[14, 15] nor on prior glucagon dosing [16]. At high circulating insulin concentrations (50-
60 mIU/l), the endogenous glucose production (EGP) is completely inhibited [17], and at 
insulin levels exceeding ~40 mIU/l the EGP cannot be stimulated by glucagon [13]. 
The ability of insulin to suppress the glycogenolytic response to glucagon at high insulin 
concentration is not reflected in previously published models of glucose-glucagon 
dynamics [18-20]. A comparative study found that a multiplicative relationship was 
needed to describe insulin’s inhibitory effect and glucagon’s stimulating effect on 
glycogenolysis with insulin overriding the effect of glucagon at high concentrations of 
both hormones [21]. Recently, we extended the multiplicative model by incorporating the 
interaction between insulin and glucagon on glycogenolysis [13, 22]. The model 
extension was developed using pre-clinical data from dogs and was fitted to clinical 
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human data in previous studies [23, 24]. In this paper, we aim to validate the 
multiplicative glucose-insulin-glucagon model for simulation studies in humans using 
data from eight patients with type 1 diabetes.  
Methods 
Data Collection 
Clinical data originated from a glucagon dose-finding study in eight well-controlled 
patients with type 1 diabetes (5 females, age range: 19-64 years, BMI range: 20.0-25.4 
kg/m2, HbA1c range: 6.1-7.4 %), who were insulin pump-treated and had no endogenous 
production of insulin [25]. Table S1 summarizes the patient characteristics. In brief, the 
patients completed four similar study days in random order. On each study day, patients 
arrived at the research facility in the morning in a fasting state. A subcutaneous (SC) 
insulin bolus (NovoRapid®, Novo Nordisk A/S, Bagsværd, Denmark) was administered 
via the patient’s insulin pump, aiming to lower plasma glucose to 54 mg/dl if no 
interventions were made. The insulin bolus was calculated based on each patient’s 
individual sensitivity factor, which was determined prior to the first study visit using a 
standard procedure [26]. When plasma glucose reached ≤70 mg/dl, a single SC bolus of 
either 100 µg (visit B), 200 µg (visit C), 300 µg (visit D) glucagon (GlucaGen®, Novo 
Nordisk A/S, Bagsværd, Denmark), or saline (visit A) was administered, see Figure 1. 
Blood was sampled and analyzed for plasma glucose (YSI 2300 STAT Plus, Yellow 
Springs Instrument, Ohio), plasma glucagon [27] and serum insulin aspart (Mercodia AB, 
Uppsala, Sweden). The insulin pump continuously infused insulin as a basal rate during 
the study days. The insulin infusion rate was adjusted before the first study day, to keep 
near constant blood glucose values in the fasting and resting condition. The individual 
insulin infusion basal rates were similar between study visits.  
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Models 
When applying a pharmacokinetic (PK) model, we assume that all increases in insulin 
and glucagon concentrations are due to exogenously dosed drugs so that endogenous 
production is constant or negligible. 
Insulin Pharmacokinetic Model 
Previous studies showed that a simple two-state model with identical time constants for 
absorption and elimination could be used to describe the PK of insulin aspart after SC 
dosing [28]. 
d𝑋1(𝑡)
dt
= 𝑢𝐼(𝑡) −
𝑋1(𝑡)
𝑡𝑚𝑎𝑥
 
d𝑋2(𝑡)
dt
=
𝑋1(𝑡)
𝑡𝑚𝑎𝑥
−
𝑋2(𝑡)
𝑡𝑚𝑎𝑥
 
𝐼(𝑡) =
1
𝑡𝑚𝑎𝑥
𝑋2(𝑡)
𝑊 ∙ 𝐶𝑙𝐹,𝐼
106 + 𝐼𝑏 
Table 1 lists the interpretations of the insulin PK model parameters and their units. The 
insulin concentration in serum is the sum of external rapid acting insulin dosage and basal 
infusion. The model assumes steady state insulin concentration, Ib, maintained by the 
basal infusion when no exogenous rapid acting insulin is dosed.  
Glucagon Pharmacokinetic Model 
A two-state model with different absorption and elimination rate constants can describe 
glucagon PK after SC dosing [23]. 
d𝑍1(𝑡)
dt
= 𝑢𝐶(𝑡) − 𝑘1𝑍1(𝑡) 
d𝑍2(𝑡)
dt
= 𝑘1𝑍1(𝑡) − 𝑘2𝑍2(𝑡) 
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𝐶(𝑡) =
𝑘2𝑍2(𝑡)
𝑊 ∙ 𝐶𝑙𝐹,𝐶
+ 𝐶𝑏 
Table 1 lists the interpretations of the glucagon PK model parameters and their units. The 
glucagon concentration in plasma is the sum of constant endogenous glucagon, Cb, and 
external glucagon dosage. The model does not include an endogenous response to 
hypoglycemia.  
Glucose Pharmacodynamic Model 
The glucose PD model was originally derived by Hovorka et al. [29, 30] and further 
extended by Wendt et al. [23]. 
d𝑄1(𝑡)
dt
= −𝐹01 − 𝐹𝑅 − 𝑆𝑇𝑥1(𝑡)𝑄1(𝑡) + 𝑘12𝑄2(𝑡) + 𝐺𝐺𝐺(𝑡) + 𝐺𝐺𝑁𝐺 
d𝑄2(𝑡)
dt
= 𝑆𝑇𝑥1(𝑡)𝑄1(𝑡) − [𝑘12 + 𝑆𝐷𝑥2(𝑡)]𝑄2(𝑡) 
𝐺𝐺𝐺(𝑡) =
1 − 𝑆𝐸𝑥3(𝑡)
1 − 𝑆𝐸𝐼𝑏
((𝐸𝑚𝑎𝑥 − 𝐺𝐺𝑁𝐺)
𝐶(𝑡)
𝐶𝐸50 + 𝐶(𝑡)
) 
𝐺(𝑡) =
𝑄1(𝑡)
𝑉
 
d𝑥1(𝑡)
dt
= 𝑘𝑎1[𝐼(𝑡) − 𝑥1(𝑡)] 
d𝑥2(𝑡)
dt
= 𝑘𝑎2[𝐼(𝑡) − 𝑥2(𝑡)] 
d𝑥3(𝑡)
dt
= 𝑘𝑎3[𝐼(𝑡) − 𝑥3(𝑡)] 
Table 1 lists the interpretations of the glucose PD model parameters and their units. The 
endogenous glucose production is the sum of glycogenolysis, GGG, and gluconeogenesis, 
GGNG. The gluconeogenesis is fixed at 6 µmol/kg/minute [10]. F01 is constant when 
plasma glucose concentration exceeds 81 mg/dl [30]. The renal glucose clearance is zero 
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when plasma glucose concentrations do not exceed 162 mg/dl [30]. The glucose volume 
of distribution is fixed at 160 ml/kg [29]. 
Model Fitting 
All model fitting was executed in R version 3.1.0 Spring Dance using the additional 
packages CTSM-R and numDeriv [31]. Additional data handling was carried out using 
Microsoft Excel 2013. Unless stated otherwise, the results are reported as means with 
95% Wald confidence intervals (CI) derived from the inverse Hessian, which provides 
the curvature of the log-likelihood function [32].  
We fitted the insulin PK model using ordinary differential equations (ODEs) and 
estimated the log-normally distributed observation noise variance using maximum 
likelihood (ML) [33]. Due to missing insulin data around the expected time of maximum 
insulin concentration both tmax and ClF,I were estimated using maximum a posteriori 
(MAP) while Ib was estimated using ML. Prior distributions of tmax and ClF,I were 
reported in [28] and further information regarding tmax was extracted from the product 
monograph on insulin aspart [34]. Table S2 lists the prior parameter distributions. No 
prior correlation between tmax and ClF,I was assumed. 
Insulin PK parameters were optimized on a subject basis to datasets from all four visits (8 
parameter sets reported). Despite SC infusion rates of short acting insulin (i.e. the basal 
rates) were similar per subject for all study visits, the baseline insulin concentration 
varied as evident from the raw data plotted in Figures S1-S7. Therefore, the parameter 
describing the steady state insulin level was estimated separately for each visit. Using the 
subject specific optimized parameters, the insulin PK was simulated every minute and 
used as input to the PD model. 
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We fitted the glucagon PK model for visits B, C, and D using ordinary differential 
equations (ODEs) and estimated the log-normally distributed observation noise variance 
using ML. Plasma glucagon was sampled adequately to perform ML estimation of all 
parameters in the glucagon PK model. There was some uncertainty regarding the exact 
dosing time of the glucagon bolus, which was given after the blood sampling at time zero 
but before the next blood sampling five minutes after. Due to this uncertainty, we 
estimated the dosing time by choosing the discrete dosing time within the five-minute 
interval yielding the fit with the highest likelihood value and kept this updated dosing 
time throughout the data fitting and handling.  
As the absolute elimination rate of glucagon is limited by the absorption rate, glucagon 
exerts flip-flop kinetics [35]. To avoid the flip-flop phenomenon and to reduce the 
population variation in the two time constants, k2 was parameterized such that it was 
greater than k1 in all datasets.  
The glucagon PK parameters were estimated to the datasets from visits with glucagon 
dosing (24 parameter sets, data not shown) and the PK simulated every minute to be used 
as input when fitting the PD model. On a subject basis, the glucagon PK parameters were 
optimized to datasets from all three glucagon visits (8 parameter sets reported). Due to 
the limited amount of data, we assumed the parameters did not differ between the visits.   
The data following administration of saline (visit A) were not fitted to the glucagon PK 
model but described using linear interpolation between measurements. These interpolated 
data were used as inputs to the PD model.  
The PD model was fitted using ordinary differential equations (ODEs) and the log-
normally distributed observation noise variance estimated using ML. The remaining 
parameters (Emax, CE50, F01, k12, ka1, ka2, ka3, SD, SE, ST) were estimated using MAP with 
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priors inspired by literature [22, 29]. We used priors for the time constants rather than 
fixing the four parameters [30]. The time constants and the insulin sensitivities were log-
transformed during the parameter estimation. Table S2 lists the prior PD model parameter 
distributions. The PD model parameters have units yielding a glucose output measured in 
mmol/l, but the output is converted and graphically displayed with units of mg/dl. We 
assumed no prior correlation between parameters. As previously mentioned, glucose 
volume of distribution and gluconeogenesis were both fixed based on literature [10, 29]. 
Ib was fixed for each subject based on their average steady state insulin concentration. 
The final PD model parameters were obtained by optimizing the fit to all non-outlier 
visits by each subject (8 parameter sets reported).  
Pharmacodynamic Model Validation 
To quantify the simulation accuracy of the model on datasets not used for parameter 
optimization, the bias was calculated by the mean prediction error (MPE) and the 
precision calculated by the mean absolute prediction error (MAPE). MPE and MAPE 
were calculated as percentages [36].  
𝑀𝑃𝐸 =
1
𝑁
∑[(
𝑝𝑟𝑒𝑑𝑗 − 𝑜𝑏𝑠𝑗
𝑜𝑏𝑠𝑗
) × 100]
𝑁
𝑗=1
 
𝑀𝐴𝑃𝐸 =
1
𝑁
∑[(
|𝑝𝑟𝑒𝑑𝑗 − 𝑜𝑏𝑠𝑗|
𝑜𝑏𝑠𝑗
) × 100]
𝑁
𝑗=1
 
predj and obsj are the jth predicted and observed value, respectively of a total of N 
observations. If the MPE is less than ±15% and the MAPE is less than 20%, we regard 
the model fit as accurate, precise and suitable for simulations. Cut-off limits were based 
on categorizing some fits in “good”, “medium” and “bad” prior to knowledge of those 
fits’ MPE and MAPE values by two independent raters. The limits were chosen so that all 
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fits categorized as “good” by both raters would be accepted and all fits categorized as 
“bad” by both raters would not meet the acceptance criteria.  
The PD model validation was carried out as a 4-fold leave-one-out cross-validation 
leaving all data from one visit out per fold. As each subject participated in four visits, 
each subject had four training datasets comprised of data from three visits and four 
corresponding test datasets with data from one visit: 
 Training: B-C-D, Test: A 
 Training: A-C-D, Test: B 
 Training: A-B-D, Test: C 
 Training: A-B-C, Test: D 
Thus, all four visits were used for testing once without being used for optimization during 
that fold. If the MAPE of a test-fit exceeded 50 %, the test visit was considered an outlier 
and removed from further analysis. After removal of the outlier dataset another round of 
leave-one-out was performed on the remaining three datasets. To validate the PD model 
in a subject, we required that at least one PD model test-fit of a dataset from a glucagon 
visit (B, C or D) was accepted. 
Results 
Table 2 lists the estimated insulin PK model parameters. The fasting steady state insulin 
concentration had day-to-day variation within patients of up to 6 mU/l and ranged from 
3.0 mU/l to 22.6 mU/l between subjects. The mean of all steady state insulin 
concentrations was 9.7 mU/l. The time to maximum concentration ranged from 40.8 to 
68.5 minutes and the apparent clearance ranged 14.8-26.8 ml/kg/minute. 
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Table 3 lists the estimated glucagon PK model parameters and the calculated time to 
maximum concentration. The fasting steady state glucagon concentrations were similar in 
the range 7.6-11.6 pg/ml for all patients except patient 8 who had a concentration of 19.0 
pg/ml. The absorption and elimination time constants ranged from 0.022-0.058 minute-1 
and 0.058-0.28 minute-1, yielding a calculated time to maximum concentration of 7.5-
19.1 minutes. The apparent clearance ranged from 91 to 200 ml/kg/minute.  
Table 4 provides an overview of the leave-one-out cross-validation procedure of the PD 
model.  The MPE and MAPE for the test-fits are listed together with a dichotomous 
decision of acceptance or not using the criteria outlined in section “Pharmacodynamic 
Model Validation”. Based on the MAPE during leave-one-out, we excluded four outlier 
datasets from further analysis and these four patients had a second round of leave-one-out 
including the remaining three datasets. Overall, the test-fit was accepted two to three 
times out of three in three patients, and one to two times out of four in four patients. In 
patient 8 we did not accept any of the test-fits even after removal of an outlier dataset. 
Figure 2 presents examples of PD model test-fits and corresponding MPE and MAPE 
values of the test-fits both passing and violating the acceptance criteria. In summary, the 
PD model successfully predicted unseen glucose data at least once in seven patients and 
therefore we regard the PD model as validated and suitable for simulation studies of these 
seven type 1 diabetes patients.  
Table 5 lists the PD model parameters optimized to all non-outlier visits in each patient 
with mean parameter values and 95% CI. The parameter describing the maximum EGP at 
steady state insulin concentration, Emax, ranged 56-84 µmol/kg/minute. The glucagon 
concentration at which the effect is half maximum, CE50, ranged 141-436 pg/ml. 
Extrapolated to zero insulin and at basal glucagon concentration, the EGP ranged 7-13.3 
µmol/kg/minute. According to the inverse of the parameter describing the insulin 
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sensitivity to EGP, SE, the calculated insulin concentration at which the effect of 
glucagon shuts off ranged 22-71 mU/l. Figures 3 and S1-S7 provide simulations of 
patient optimized PD model fits and data. 
Discussion 
We fitted simple PK models of serum insulin and plasma glucagon after SC bolus 
administrations of the hormones. The simulated concentrations of insulin and glucagon 
were used as inputs to the PD model. We sought to validate the PD model for simulations 
in eight type 1 diabetes patients and succeeded in seven. Finally, we estimated the 
patient’s individual PD model parameters. 
The fitted insulin PK model assumes that all changes in serum insulin concentration are 
due to SC insulin dosing. This is a valid assumption as no patients had measureable 
endogenous insulin secretion after glucagon stimulation [25]. Patients’ insulin levels are 
at steady state when no insulin bolus is administered. 
The clinical study focused on generating data describing the effect of glucagon on 
glucose, and therefore only few data points describing the insulin PK were obtained. The 
insulin PK data were sampled very sparsely around the expected time of maximum 
concentration. The missing data did not allow for ML estimation of the insulin PK model. 
However, using literature informed prior distributions of both tmax and ClF,I and 
optimizing for all four visits simultaneously we obtained reasonable fits by MAP 
estimation [28, 34].  
As the insulin PK model was fitted to in-hospital sedentary patients, its application in 
patients with type 1 diabetes outside the hospital setting may be limited due to numerous 
factors affecting insulin absorption rate, sensitivity and bioavailability. Such factors could 
be accounted for by introducing time-variant model parameters, which was beyond the 
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scope of this work [9, 37, 38]. Especially, differences in insulin absorption could explain 
the observed intra-patient variation in steady state insulin concentration despite equal 
basal rates at all four visits.  
Patients with type 1 diabetes have a blunted glucagon response to hypoglycemia 
compared to healthy subjects [39]. The fitted glucagon PK model assumes that all 
changes in plasma glucagon concentration are due to SC dosing and that the endogenous 
production is constant or negligible. To verify this assumption, we determined the size of 
the endogenous glucagon response to hypoglycemia during the saline day and compared 
it to simulations of glucagon PK in each of the eight subjects (data not shown). We found 
that exogenous glucagon doses of 1-10 µg would equal the plasma glucagon increase to 
hypoglycemia. Since the endogenous glucagon response to hypoglycemia was at most 
one tenth of the administered dose during the glucagon days, this confirmed that the 
endogenous response during these days was negligible compared to the exogenous dosed 
glucagon. However, the endogenous response was not negligible during the saline day 
and therefore the glucagon PK model was not applicable to those datasets. 
The glucagon PK fit was challenged by the short time to maximum concentration 
combined with the uncertainty of the exact dosing time of glucagon. This could 
potentially result in an error in time to maximum concentration of up to ±4 minutes. 
However, this possible deviation has minor impact on the PD model fit when the 
glucagon PK fit is used as an input. Despite the dosing time uncertainty, the calculated 
times to maximum concentration are within reasonable range of population averages 
reported in the literature [28, 40]. In the model by Haidar et al. [28], the glucagon 
absorption rate and elimination rate were identical which we only observed in patient 4. 
In the remaining seven patients, the elimination rate was significantly higher than the 
absorption rate. Moreover, having different absorption and elimination rate constants we 
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observed a higher clearance rate. Compared to Haidar et al., we found lower basal 
concentration of glucagon, which could be attributed to differences in the assays for 
analysis of plasma glucagon concentration [26]. 
Despite using informed priors for all PD model parameters, some optimized parameters 
are very different from the population mean and vary considerably more than originally 
listed in Hovorka et al. [29]. However, the original reference is based on a population of 
only six subjects, which makes it unlikely that all true population variations were 
captured, and we believe, therefore, that our parameter estimates are still valid. Similarly, 
with a population of eight subjects, we did not fit a population model but focused on 
estimating parameters for each subject individually. 
The limited human data on EGP response to glucagon are consistent with data from dogs 
[22]. As the human response to high glucagon concentrations has not been thoroughly 
investigated, the dog data provide best guesses of the human values. The maximum EGP 
due to glucagon and glucagon concentration at half-maximum effect at basal insulin 
average around 60 µmol/kg/minute and 300 pg/ml in dogs [22]. Our results match the 
reference values and therefore seem plausible.  
We found that EGP at zero insulin and basal glucagon is somewhat lower than previous 
publications, which state 10-20 µmol/kg/minute [29] and ~30 µmol/kg/minute [22]. This 
might be due to the fixation of gluconeogenesis at 6 µmol/kg/minute [10], which is 
increased in subjects with poorly controlled type 1 diabetes compared to the present well-
controlled patients or healthy subjects [25, 41]. Assuming the proposed model of EGP is 
correct, the insulin concentration at which the glycogenolysis, hence the effect of 
glucagon, shuts off is reasonable compared to the limited publications showing 
glycogenolysis at various insulin concentrations [22, 42]. Rizza et al. found that the 
glucose production was suppressed by insulin beyond approximately 60 mU/l [17]. El 
page 16 of 34 
 
Youssef et al. found that at serum insulin concentrations beyond 40 mU/l glucagon 
concentrations below 450 pg/ml did not stimulate EGP [13]. Further clinical studies are 
needed to investigate whether high insulin concentrations completely suppress the effect 
of glucagon or whether the maximum EGP is still attainable though at higher glucagon 
concentrations. 
A major limitation to some of the previously published models describing the effect of 
glucagon on glucose production is lack of validation [18, 21]. We were able to mimic 
never-before-seen glucose data at least once and at most three times in seven of the eight 
subjects using the presented glucose PD model. We did not expect to accept the test-fit of 
all non-outlier datasets in each subject as the visits often described complimentary 
dynamics of the glucose-insulin-glucagon relationship; for instance the placebo day had 
very limited information on how different glucagon concentrations affects EGP as 
glucagon levels were changing very little. On the contrary, the placebo datasets were rich 
in information about the effects of insulin on plasma glucose. Some glucagon datasets 
had few observations of the effects of insulin on EGP as the plasma glucose some days 
reached the bolus threshold of 70 mg/dl quickly e.g. in subject 2 and 7 shown in Figure 
S2 and Figure 3, respectively. As an example, this difference in data sampling can 
explain why it was not possible to validate the model using subject 2’s visit B as the test 
dataset. For this particular patient, the placebo visit was stopped early and therefore does 
not contain much information about the insulin dynamics. Moreover, the insulin only 
phase of visit B lasted nearly five hours and only two hours during visit C and D. Leaving 
visit B out of the training dataset does not provide the model with enough information to 
predict the insulin dynamics present in visit B. We noted that in most cases when the test-
fit was not accepted there was a monotone bias in the residuals yielding almost equal 
values of absolute MPE and MAPE, see Table 4. This bias indicates that the test-fit 
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would either over- or undershoot compared to data and thus both insulin and glucagon 
dynamics of the test dataset were not well described by the training datasets. Analyzing 
the PD model parameters during leave-one-out in Tables S3-S10, we observed that when 
a test-fit could not be accepted, usually one or more parameters were outside the CI 
obtained when fitting to all non-outlier data. Therefore, failing to accept the test-fit 
during a fold is not necessarily a sign of an incorrect model structure. Rather it could 
emphasize that the test dataset contains unique information about the dynamics, which 
are not present in any of the training datasets [43]. However, in four patients one dataset 
was so different from the other three datasets that it had to be excluded from the final PD 
model estimation as it would otherwise affect the parameters and yield bad fits for all 
four study days.  
Simulation models are rarely validated on unseen data. The only glucose model including 
glucagon that is currently validated and FDA approved has undisclosed parameter values 
and can only be accessed by payment [19, 44]. We believe that this paper is a step 
towards more openly sharing simulation models that will allow more research groups to 
test dual-hormone dosing strategies and control algorithms for managing diabetes before 
carrying out expensive simulations or clinical trials. 
Conclusion 
We have successfully validated a model describing the glucose-insulin-glucagon 
dynamics in seven type 1 diabetes subjects using leave-one-out cross-validation. We have 
reported model parameter sets with uncertainties for each subject, which could be used 
for in silico experiments. Simulations could also aid in optimizing treatment for type 1 
diabetes patients such as glucagon dosing strategies for preventing hypoglycemia and 
tuning control strategies for an AP. 
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Tables 
Table 1: Interpretation of insulin PK (top rows), glucagon PK (middle rows) and glucose 
PD (bottom rows) model parameters and their units. 
Parameter Unit Interpretation 
X1(t) U insulin mass due to exogenous dosing, in SC tissue 
X2(t) U insulin mass due to exogenous dosing, in serum 
uI(t) U/minute insulin dose 
tmax minutes time from dose to maximum serum concentration 
W kg body weight 
ClF,I ml/kg/minute apparent insulin clearance 
Ib mU/l steady state insulin concentration 
I(t) mU/l insulin concentration in serum 
Z1(t) pg glucagon mass due to exogenous dosing, in SC tissue 
Z2(t) pg glucagon mass due to exogenous dosing, in plasma 
uC(t) pg/minute glucagon dose 
k1 minute
-1 absorption rate constant 
k2 minute
-1 elimination rate constant 
ClF,C ml/kg/minute apparent glucagon clearance 
Cb pg/ml steady state glucagon concentration 
C(t) pg/ml glucagon concentration in plasma 
Q1(t) µmol/kg glucose mass per W in the accessible compartment 
Q2(t) µmol/kg glucose mass per W in the non-accessible compartment 
x1(t) mU/l remote effects of insulin on glucose transport 
x2(t) mU/l remote effects of insulin on glucose disposal 
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x3(t) mU/l remote effects of insulin on glycogenolysis 
G(t) mmol/l glucose concentration in plasma 
GGG(t) µmol/kg/minute glucose production due to glycogenolysis 
GGNG µmol/kg/minute glucose production due to gluconeogenesis  
F01 µmol/kg/minute insulin independent glucose flux 
FR µmol/kg/minute renal glucose clearance 
ST minute
-1/(mU/l) insulin sensitivity of glucose transport  
SD minute
-1/(mU/l) insulin sensitivity of glucose disposal 
SE l/mU insulin sensitivity on glycogenolysis 
k12 minute
-1 transfer rate constant from the non-accessible to the 
accessible compartment 
ka1 minute
-1 insulin deactivation rate constant 
ka2 minute
-1 insulin deactivation rate constant 
ka3 minute
-1 insulin deactivation rate constant 
Emax µmol/kg/minute maximum EGP at basal insulin concentration 
CE50 pg/ml glucagon concentration yielding half of maximum EGP 
V ml/kg glucose volume of distribution 
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Table 2: Summary of insulin PK model parameters for simulation with range of means 
and 95% CI or mean and 95% CI. 
Patient Ib 
[mU/l] 
tmax 
[min] 
ClF,I 
[ml/kg/min] 
1 6.6-7.8 (6.0-8.3) 57.6 (50.9-64.3) 18.9 (17.3-20.6) 
2 10.0-11.2 (9.1-12.0) 57.3 (48.8-65.9) 18.5 (16.1-21.2) 
3 10.3-13.4 (9.7-14.0) 40.8 (37.6-44.0) 14.8 (13.6-16.1) 
4 7.8-9.4 (7.4-9.9) 67.9 (63.5-72.2) 17.4 (16.6-18.3) 
5 5.2-8.2 (4.8-8.8) 48.5 (44.7-52.4) 17.3 (15.7-19.0) 
6 3.0-8.5 (2.3-9.4) 46.5 (41.7-51.3) 24.6 (22.9-26.3) 
7 16.8-22.6 (15.6-23.6) 68.5 (60.6-76.4) 23.7 (21.3-26.4) 
8 4.7-9.1 (4.4-9.6) 55.4 (49.6-61.2) 26.8 (24.8-29.0) 
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Table 3: Summary of glucagon PK model parameters for simulation with mean and 95% 
CI. 
Patient Cb 
[pg/ml] 
k1 
[min-1] 
k2 
[min-1] 
ClF,C 
[ml/kg/min] 
tmax 
[min] 
1 10.7  
(9.4-12.0) 
0.042  
(0.036-0.048) 
0.14 
(0.10-0.22) 
94 
(83-105) 
12.2 
2 7.6  
(6.9-8.3) 
0.056 
(0.052-0.062) 
0.26 
(0.18-0.38) 
106 
(96-116) 
7.5 
3 7.6  
(5.9-9.3) 
0.022 
(0.018-0.028) 
0.10 
(0.06-0.17) 
114 
(96-132) 
19.1 
4 10.9  
(9.2-12.6) 
0.058 
(0.011-0.313) 
0.058 
(NA) 
159 
(133-184) 
17.3 
5 8.7  
(7.7-9.8) 
0.038 
(0.032-0.044) 
0.19 
(0.13-0.29) 
200 
(176-223) 
10.7 
6 8.9  
(7.8-10.0) 
0.035 
(0.031-0.040) 
0.28 
(0.19-0.41) 
125 
(111-138) 
8.6 
7 11.6  
(10.1-13.0) 
0.035 
(0.030-0.041) 
0.25 
(0.16-0.39) 
136 
(120-152) 
9.2 
8 19.0  
(16.1-22.0) 
0.052 
(0.037-0.072) 
0.090 
(0.04-0.26) 
91 
(78-105) 
14.5 
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Table 4: PD model validation using leave-one-out cross-validation. Initially, data from 
three visits are used for training the model, i.e. optimizing model parameters, and data 
from the fourth visit is used for testing the model with the optimized parameters. *A test-
fit with MPE or MAPE exceeding 50% is considered an outlier. The outlier dataset is 
removed and another round of leave-one-out cross-validation is performed on the 
remaining three visits. 
Patient Training visits Test visit MPE, % MAPE, % Accept? (Y/N) 
1 
BCD A -25.0 25.0 N 
ACD B -11.3 13.7 Y 
ABD C 78.8 78.8 N* 
ABC D 3.3 25.5 N 
BD A -10.3 11.1 Y 
AD B 10.4 13.1 Y 
AB D 4.0 21.3 N 
2 
BCD A 29.1 29.8 N 
ACD B -18.2 18.7 N 
ABD C -6.3 7.5 Y 
ABC D 6.3 10.0 Y 
3 
BCD A 10.3 17.4 Y 
ACD B -2.3 8.6 Y 
ABD C 23.4 24.6 N 
ABC D -20.1 20.1 N 
4 
BCD A -17.3 18.9 N 
ACD B -9.4 11.1 Y 
ABD C -23.6 23.7 N 
ABC D 38.2 38.4 N 
5 
BCD A -13.4 13.4 Y 
ACD B -30.0 30.4 N 
ABD C -16.3 21.3 N 
ABC D 74.6 74.6 N* 
BC A -1.7 4.5 Y 
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AC B -9.8 14.1 Y 
AB C -7.5 17.4 Y 
6 
BCD A -23.5 24.2 N 
ACD B -4.5 12.0 Y 
ABD C 59.0 59.0 N* 
ABC D -8.6 16.3 Y 
BD A -13.7 16.9 Y 
AD B 16.7 17.5 N 
AB D 4.7 15.8 Y 
7 
BCD A 43.0 43.3 N 
ACD B -19.0 19.0 N 
ABD C -2.9 19.0 Y 
ABC D 6.0 8.0 Y 
8 
BCD A -8.0 12.4 Y 
ACD B -32.9 33.0 N 
ABD C -14.5 24.2 N 
ABC D 174.1 174.1 N* 
BC A -26.2 26.2 N 
AC B -24.6 24.6 N 
AB C 42.5 42.5 N 
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Table 5: Summary of PD model parameters for simulation with mean and 95% CI.  
ID Data CE50 
[pg/ml] 
Emax 
[µmol/kg/min] 
F01 
[µmol/kg/min] 
k12*10-4 
[min-1] 
ka1*10-4 
[min-1] 
ka2*10-4 
[min-1] 
ka3*10-4 
[min-1] 
SD*10-4 
[min-1/(mU/l)] 
SE*10-4 
[(mU/l)-1] 
ST*10-4 
[min-1/(mU/l)] 
1 
ABD 436 
(355-517) 
56.4 
(51.1-61.8) 
14.2 
(12.9-15.5) 
244 
(181-330) 
16 
(7-35) 
522 
(221-1233) 
215 
(59-778) 
1.5 
(0.6-3.3) 
155 
(83-289) 
23 
(16-31) 
2 
ABCD 405 
(339-471) 
67.4 
(59.3-75.5) 
13.8 
(12.8-14.7) 
285 
(223-363) 
15 
(7-35) 
495 
(236-1039) 
231 
(137-389) 
1.2 
(0.6-2.3) 
334 
(232-481) 
19 
(15-25) 
3 
ABCD 401 
(327-475) 
57.4 
(49.8-65.0) 
15.5 
(14.2-16.8) 
397 
(277-568) 
18 
(8-42) 
548 
(268-1121) 
327 
(168-638) 
1.4 
(0.7-2.5) 
237 
(183-308) 
25 
(17-36) 
4 
ABCD 285 
(226-344) 
84.4 
(73.9-94.8) 
12.8 
(11.3-14.4) 
213 
(157-289) 
18 
(9-36) 
437 
(183-1044) 
68 
(42-113) 
2.0 
(1.0-3.8) 
415 
(347-496) 
18 
(13-25) 
5 
ABC 339 
(251-427) 
65.4 
(53.8-77.1) 
12.0 
(10.6-13.5) 
281 
(194-406) 
15 
(7-32) 
517 
(223-1201) 
235 
(95-586) 
1.1 
(0.4-2.6) 
229 
(127-415) 
31 
(20-47) 
6 
ABD 424 
(333-515) 
60.1 
(46.3-74.0) 
13.1 
(11.7-14.5) 
238 
(172-330) 
10 
(4-22) 
353 
(102-1221) 
74 
(23-232) 
2.6 
(1.1-6.2) 
404 
(185-882) 
21 
(14-32) 
7 
ABCD 141 
(96-187) 
78.0 
(68.9-87.1) 
14.2 
(12.2-16.1) 
358 
(252-509) 
49 
(23-105) 
624 
(319-1221) 
178 
(69-459) 
4.4 
(3.2-6.0) 
140 
(99-199) 
21 
(16-29) 
8 
ABC 307 
(228-386) 
75.3 
(61.5-89.1) 
13.4 
(11.4-15.4) 
289 
(197-424) 
37 
(18-75) 
518 
(203-1324) 
154 
(68-348) 
4.2 
(2.8-6.5) 
463 
(377-569) 
29 
(20-42) 
page 32 of 34 
 
Figures 
 
Figure 1: Schematic design of the study days. Baseline blood samples were taken at time 
–(X+Y). An insulin bolus was given after Y minutes. In a few cases, multiple insulin 
boluses had to be administered to lower the plasma glucose sufficiently. When the plasma 
glucose measured below 70 mg/dl, a saline or glucagon bolus was given depending on 
the study day. At 180 or 240 minutes after the saline/glucagon bolus the experiment was 
stopped. Basal insulin infusion continued throughout the experiment. From t=–x to t=0, 
plasma glucose was measured every 15-30 minutes, while plasma glucagon and serum 
insulin were measured every 60 minutes. Plasma glucose was measured every 5 minutes 
from t=0 to t=60, every 10 minutes from t=60-120 and then every 15 minutes. Plasma 
glucagon and serum insulin were measured every 5 minutes from t=0 to t=15, every 15 
minutes from t=15 to t=60, every 30 minutes from t=60 to t=120, and then every 60 
minutes. 
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Figure 2: Examples of validation PD model fits with “good”, “medium” and “bad” MPE 
and MAPE. Top graph is test of patient 2’s visit C (accepted). Middle graph is test of 
patient 1’s visit B (accepted). Bottom graph is test of patient 8’s visit B (not accepted).   
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Figure 3: Data from all patient 7’s visits (left to right: visit A to D) with insulin PK model 
fits (top row, logarithmic y-axes) and glucagon linear interpolation or PK model fits 
(middle row, logarithmic y-axes) both used as inputs to the glucose PD model for 
simulation built with data from all four visits (bottom row). The triangles indicate dose 
time of the insulin and glucagon boluses, respectively.  
